Rpo LLC Purchases New Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Rpo LLC acquired a new position in AbCellera Biologics Inc. (NASDAQ:ABCL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,937 shares of the company’s stock, valued at approximately $61,000. AbCellera Biologics accounts for 0.1% of Rpo LLC’s investment portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. DKM Wealth Management Inc. acquired a new stake in shares of AbCellera Biologics in the fourth quarter worth $29,000. State of New Jersey Common Pension Fund D purchased a new stake in AbCellera Biologics in the 4th quarter worth about $36,000. Diametric Capital LP acquired a new stake in AbCellera Biologics during the 4th quarter worth about $53,000. IMG Wealth Management Inc. purchased a new position in AbCellera Biologics during the 4th quarter valued at about $56,000. Finally, Raymond James Financial Inc. acquired a new position in shares of AbCellera Biologics in the 4th quarter valued at about $57,000. 61.42% of the stock is currently owned by hedge funds and other institutional investors.

AbCellera Biologics Price Performance

Shares of AbCellera Biologics stock opened at $2.22 on Thursday. The stock has a 50-day simple moving average of $2.79 and a 200-day simple moving average of $2.81. AbCellera Biologics Inc. has a 52-week low of $2.02 and a 52-week high of $4.75. The firm has a market cap of $661.53 million, a price-to-earnings ratio of -3.64 and a beta of 0.45.

Analyst Ratings Changes

ABCL has been the subject of several research reports. KeyCorp decreased their price target on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Stifel Nicolaus lowered their price target on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, Benchmark reaffirmed a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.